AR095611A1 - Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) - Google Patents

Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)

Info

Publication number
AR095611A1
AR095611A1 ARP140101236A ARP140101236A AR095611A1 AR 095611 A1 AR095611 A1 AR 095611A1 AR P140101236 A ARP140101236 A AR P140101236A AR P140101236 A ARP140101236 A AR P140101236A AR 095611 A1 AR095611 A1 AR 095611A1
Authority
AR
Argentina
Prior art keywords
antibodies
cyclass
hpac1
join
receptor
Prior art date
Application number
ARP140101236A
Other languages
English (en)
Inventor
Eva Hamburger Agnes
Xu Cen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR095611A1 publication Critical patent/AR095611A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Anticuerpos y fragmentos de unión al antígeno de los mismos que se unen a la PAC1 humana. También se proveen ácidos nucleicos que codifican los anticuerpos y los fragmentos de unión al antígeno de los mismos, vectores y células que los codifican. Los anticuerpos y los fragmento de unión al antígeno de los mismos pueden inhibir la unión de PAC1 al polipéptido activador de adenilato ciclasa pituitaria (PACAP), y son de utilidad en numerosos trastornos relacionados con PAC1, incluyendo el tratamiento y/o la prevención de trastornos de cefalea, inclusive la migraña.
ARP140101236A 2013-03-15 2014-03-17 Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) AR095611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792678P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095611A1 true AR095611A1 (es) 2015-10-28

Family

ID=50439531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101236A AR095611A1 (es) 2013-03-15 2014-03-17 Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)

Country Status (24)

Country Link
US (7) US9676851B2 (es)
EP (2) EP3683237A1 (es)
JP (3) JP6283408B2 (es)
KR (1) KR102215405B1 (es)
CN (1) CN105143267B (es)
AP (1) AP2015008732A0 (es)
AR (1) AR095611A1 (es)
AU (2) AU2014228924B2 (es)
CA (1) CA2906737C (es)
CL (1) CL2015002750A1 (es)
CR (1) CR20150575A (es)
EA (1) EA032830B1 (es)
ES (1) ES2770976T3 (es)
HK (2) HK1218554A1 (es)
IL (2) IL241382A0 (es)
MA (1) MA38478A1 (es)
MX (1) MX2015013181A (es)
PE (1) PE20151923A1 (es)
PH (1) PH12015502126A1 (es)
SG (1) SG11201507416WA (es)
TN (1) TN2015000425A1 (es)
TW (2) TW201902931A (es)
UY (1) UY35483A (es)
WO (1) WO2014144632A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109451728A (zh) * 2016-04-15 2019-03-08 奥尔德生物制药公司 抗pacap抗体及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6956631B2 (ja) 2014-09-15 2021-11-02 アムジェン インコーポレイテッド 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
CA2983041A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
CA3076630A1 (en) * 2017-10-04 2019-04-11 Amgen Inc. Transthyretin immunoglobulin fusions
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
WO2019126398A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
AU2019246983A1 (en) 2018-04-02 2020-10-29 Amgen Inc. Erenumab compositions and uses thereof
AU2019250882A1 (en) 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
EP3990493A1 (en) 2019-06-28 2022-05-04 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
CA3227990A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
WO2023051786A1 (zh) * 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
WO2024171078A1 (en) 2023-02-14 2024-08-22 H. Lundbeck A/S Treatment of opiod-induced pain

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5486472A (en) 1990-03-17 1996-01-23 Takeda Chemical Industries, Ltd. Monoclonal antibodies to PACAP
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
EP0618291A3 (en) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
ATE400651T1 (de) 1993-09-10 2008-07-15 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
US6462016B1 (en) 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
PL345583A1 (en) 1998-07-20 2001-12-17 Sod Conseils Rech Applic Peptide analogues of pacap
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4555089B2 (ja) * 2002-11-15 2010-09-29 モーフオテク・インコーポレーテツド ｉｎｖｉｔｒｏ免疫感作により創製されたハイブリドーマからの抗体の高生産量の生成方法
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
AU2005209331A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
EP2048162A4 (en) 2006-08-08 2010-12-01 Univ Kyoto NEW MONOCLONAL ANTIBODY AND ITS USE
WO2009003489A1 (en) 2007-07-02 2009-01-08 Natimmune A/S CaOU-1 EPITOPE BINDING POLYPEPTIDES
WO2009033489A2 (en) 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CN101434649B (zh) 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
SG10201406930UA (en) 2009-07-27 2014-11-27 Nocicepta Llc Methods For Treatment Of Pain
JP2013505707A (ja) * 2009-09-25 2013-02-21 上海抗体薬物国家工程研究中心有限公司 コンピュータ支援設計により高親和性の抗体又はタンパク質分子を得る方法
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
JP5767207B2 (ja) * 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
MX348071B (es) * 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
CN102936303A (zh) * 2011-08-15 2013-02-20 沈阳欧陆科技发展有限公司 一种高氯含量的氯化聚氯乙烯树脂的合成方法
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
KR102115438B1 (ko) 2012-05-21 2020-05-27 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109451728A (zh) * 2016-04-15 2019-03-08 奥尔德生物制药公司 抗pacap抗体及其用途

Also Published As

Publication number Publication date
SG11201507416WA (en) 2015-10-29
IL241382A0 (en) 2015-11-30
AU2019204980A1 (en) 2019-08-01
EP2970470B1 (en) 2019-12-04
US20170247451A1 (en) 2017-08-31
CN105143267A (zh) 2015-12-09
US20160039939A1 (en) 2016-02-11
JP2018076373A (ja) 2018-05-17
JP2019024501A (ja) 2019-02-21
EA201591791A1 (ru) 2016-03-31
JP6443870B2 (ja) 2018-12-26
US10793631B2 (en) 2020-10-06
CA2906737A1 (en) 2014-09-18
US20180362645A1 (en) 2018-12-20
TWI636064B (zh) 2018-09-21
WO2014144632A8 (en) 2015-12-30
PE20151923A1 (es) 2016-01-14
US20200172614A1 (en) 2020-06-04
TW201522375A (zh) 2015-06-16
BR112015023429A2 (pt) 2017-11-28
MX2015013181A (es) 2015-12-11
EA032830B1 (ru) 2019-07-31
AU2014228924A9 (en) 2016-06-16
CN105143267B (zh) 2020-06-26
WO2014144632A3 (en) 2014-11-20
HK1219958A1 (zh) 2017-04-21
IL262804A (en) 2018-12-31
ES2770976T3 (es) 2020-07-06
KR20150128982A (ko) 2015-11-18
CL2015002750A1 (es) 2016-03-04
US10053507B2 (en) 2018-08-21
WO2014144632A2 (en) 2014-09-18
EP3683237A1 (en) 2020-07-22
US20180094055A1 (en) 2018-04-05
TW201902931A (zh) 2019-01-16
US20160251432A1 (en) 2016-09-01
US10294298B2 (en) 2019-05-21
US9365653B2 (en) 2016-06-14
CR20150575A (es) 2016-01-06
BR112015023429A8 (pt) 2018-01-23
MA38478A1 (fr) 2017-11-30
US20150010560A1 (en) 2015-01-08
EP2970470A2 (en) 2016-01-20
US10472417B2 (en) 2019-11-12
TN2015000425A1 (en) 2017-01-03
AU2014228924A1 (en) 2015-10-01
HK1218554A1 (zh) 2017-02-24
CA2906737C (en) 2023-08-15
JP6283408B2 (ja) 2018-02-21
UY35483A (es) 2014-08-29
AU2014228924B2 (en) 2019-04-18
JP2016514458A (ja) 2016-05-23
KR102215405B1 (ko) 2021-02-10
AP2015008732A0 (en) 2015-09-30
US9822178B2 (en) 2017-11-21
PH12015502126A1 (en) 2016-01-25
US9676851B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CR20170079A (es) Agentes de unión a cd123 y usos de estos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
EA201791093A1 (ru) Антитела к cd47, способы и применение
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
PH12017500297A1 (en) Anti-lag3 antibodies and antigen-binding fragments
AR093788A1 (es) Inmunoterapia con agentes de enlace
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
CR20160145A (es) Proteínas de unión al antígeno gitr
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
EA201691078A1 (ru) Терапевтические пептиды
BR112016022841A2 (pt) cadeia j modificada
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure